1887

Abstract

Glycoprotein B (gB) of human cytomegalovirus (HCMV) is the dominating protein in the envelope of this virus and gives rise to virus-neutralizing antibodies in most infected individuals. We have previously isolated a neutralizing human antibody specific for antigenic domain 2 (AD-2) on gB, a poorly immunogenic epitope, which nevertheless is capable of eliciting potent neutralizing antibodies. In order to define parameters important for the neutralization of HCMV via gB, we have investigated the virus-neutralizing capacity and the kinetics of the interaction with AD-2 of the monomeric and dimeric forms of a single chain variable fragment (scFv) corresponding to this antibody. We demonstrate here that neutralization of HCMV via AD-2 on gB can be mediated by dimeric scFv, while monomeric fragments cannot mediate neutralization of the virus, despite a slow dissociation from the intact glycoprotein. This finding is discussed in the context of possible mechanisms for antibody-mediated virus neutralization.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-83-8-2001
2002-08-01
2020-08-14
Loading full text...

Full text loading...

/deliver/fulltext/jgv/83/8/0832001a.html?itemId=/content/journal/jgv/10.1099/0022-1317-83-8-2001&mimeType=html&fmt=ahah

References

  1. Ayata M., Sugano T., Murayama T., Sakamuro D., Takegami T., Matsumoto Y., Furukawa T.. 1994; Different antibody response to a neutralizing epitope of human cytomegalovirus glycoprotein B among seropositive individuals. Journal of Medical Virology43:386–392
    [Google Scholar]
  2. Azuma J., Kurimoto T., Tsuji S., Mochizuki N., Fujinaga S., Matsumoto Y., Masuho Y.. 1991; Phase I study on human monoclonal antibody against cytomegalovirus: pharmacokinetics and immunogenicity. Journal of Immunotherapy10:278–285
    [Google Scholar]
  3. Britt W. J., Vugler L. G.. 1992; Oligomerization of the human cytomegalovirus major envelope glycoprotein complex gB (gp55-116). Journal of Virology66:6747–6754
    [Google Scholar]
  4. Britt W. J., Vugler L., Butfiloski E. J., Stephens E. B.. 1990; Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. Journal of Virology64:1079–1085
    [Google Scholar]
  5. Burton D. R., Williamson R. A., Parren P. W.. 2000; Antibody and virus: binding and neutralization. Virology270:1–3
    [Google Scholar]
  6. Burton D. R., Saphire E. O., Parren P. W.. 2001; A model for neutralization of viruses based on antibody coating of the virion surface. Current Topics in Microbiology and Immunology260:109–143
    [Google Scholar]
  7. Drew P. D., Moss M. T., Pasieka T. J., Grose C., Harris W. J., Porter A. J.. 2001; Multimeric humanized varicella-zoster virus antibody fragments to gH neutralize virus while monomeric fragments do not. Journal of General Virology82:1959–1963
    [Google Scholar]
  8. Fowler K. B., Stagno S., Pass R. F., Britt W. J., Boll T. J., Alford C. A.. 1992; The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. New England Journal of Medicine326:663–667
    [Google Scholar]
  9. Ho M.. 1991; Cytomegalovirus: Biology and Infection . , 2nd edn. ppxix–440 New York: Plenum Medical Book Company;
  10. Hopp T. P., Pricket K. S., Price V. L., Libby R. T., March C. J., Cerretti D. P., Urdal D. L., Conlon P. J.. 1988; A short polypeptide marker sequence useful for recombinant protein identification and purification. Bio-Technology6:1204–1210
    [Google Scholar]
  11. Kalinke U., Krebber A., Krebber C., Bucher E., Plückthun A., Zinkernagel R. M., Hengartner H.. 1996; Monovalent single-chain Fv fragments and bivalent miniantibodies bound to vesicular stomatitis virus protect against lethal infection. European Journal of Immunology26:2801–2806
    [Google Scholar]
  12. Loenen W. A., Bruggeman C. A., Wiertz E. J.. 2001; Immune evasion by human cytomegalovirus: lessons in immunology and cell biology. Seminars in Immunology13:41–49
    [Google Scholar]
  13. Masuho Y., Matsumoto Y., Sugano T., Fujinaga S., Minamishima Y.. 1987; Human monoclonal antibodies neutralizing human cytomegalovirus. Journal of General Virology68:1457–1461
    [Google Scholar]
  14. Meyer H., Sundqvist V. A., Pereira L., Mach M.. 1992; Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. Journal of General Virology73:2375–2383
    [Google Scholar]
  15. Navarro D., Lennette E., Tugizov S., Pereira L.. 1997; Humoral immune response to functional regions of human cytomegalovirus glycoprotein B. Journal of Medical Virology52:451–459
    [Google Scholar]
  16. Ohizumi Y., Suzuki H., Matsumoto Y., Masuho Y., Numazaki Y.. 1992; Neutralizing mechanisms of two human monoclonal antibodies against human cytomegalovirus glycoprotein 130/55. Journal of General Virology73:2705–2707
    [Google Scholar]
  17. Ohlin M., Sundqvist V. A., Mach M., Wahren B., Borrebaeck C. A. K.. 1993; Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. Journal of Virology67:703–710
    [Google Scholar]
  18. Ohlin M., Owman H., Mach M., Borrebaeck C. A. K.. 1996; Light chain shuffling of a high affinity antibody results in a drift in epitope recognition. Molecular Immunology33:47–56
    [Google Scholar]
  19. Roost H. P., Bachmann M. F., Haag A., Kalinke U., Pliska V., Hengartner H., Zinkernagel R. M.. 1995; Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity. Proceedings of the National Academy of Sciences, USA92:1257–1261
    [Google Scholar]
  20. Roy D. M., Grundy J. E.. 1992; Evaluation of neutralizing antibody titers against human cytomegalovirus in intravenous gamma globulin preparations. Transplantation54:1109–1110
    [Google Scholar]
  21. Schoppel K., Kropff B., Schmidt C., Vornhagen R., Mach M.. 1997; The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies. Journal of Infectious Diseases175:533–544
    [Google Scholar]
  22. Snydman D. R., Werner B. G., Meissner H. C., Cheeseman S. H., Schwab J., Bednarek F., Kennedy J. L. Jr, Herschel M., Magno A., Levin M. J.. and others 1995; Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates. Pediatric Infectious Disease Journal14:34–40
    [Google Scholar]
  23. Spaete R. R.. 1991; A recombinant subunit vaccine approach to HCMV vaccine development. Transplantation Proceedings23:90–96
    [Google Scholar]
  24. Spaete R. R., Gehrz R. C., Landini M. P.. 1994; Human cytomegalovirus structural proteins. Journal of General Virology75:3287–3308
    [Google Scholar]
  25. Thorpe R., Bird C. R., Brasher M. D.. 1987; Characterisation, standardisation and control of therapeutic immunoglobulin preparations intended for intravenous use. Journal of Infection15:13–19
    [Google Scholar]
  26. Utz U., Britt W., Vugler L., Mach M.. 1989; Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. Journal of Virology63:1995–2001
    [Google Scholar]
  27. Zaia J. A.. 1993; Prevention and treatment of cytomegalovirus pneumonia in transplant recipients. Clinical Infectious Diseases17 (Suppl. 2):S392–S399
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-83-8-2001
Loading
/content/journal/jgv/10.1099/0022-1317-83-8-2001
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error